These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9583930)
1. Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed. Freemantle N; Mason J BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9583930 [No Abstract] [Full Text] [Related]
2. Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate. Pharoah P BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9553009 [No Abstract] [Full Text] [Related]
3. Statin therapy for prevention of coronary artery disease with average cholesterol levels. Gambhir DS Indian Heart J; 1999; 51(1):19-20, 105. PubMed ID: 10327772 [No Abstract] [Full Text] [Related]
4. A need to redefine the consensus on the use of statins in coronary heart disease prevention. Fruchart JC Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008 [No Abstract] [Full Text] [Related]
5. Prevention of mortality from coronary heart disease with pravastatin. Tonkin AM; Ryan EW Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675 [TBL] [Abstract][Full Text] [Related]
6. Prevention of coronary heart disease with pravastatin. Samani NJ; de Bono DP N Engl J Med; 1996 May; 334(20):1333-4; author reply 1334-5. PubMed ID: 8609957 [No Abstract] [Full Text] [Related]
8. Prevention of coronary heart disease with pravastatin. Davis DR N Engl J Med; 1996 May; 334(20):1334; author reply 1335. PubMed ID: 8609958 [No Abstract] [Full Text] [Related]
9. Prevention of coronary heart disease with pravastatin. Rogers S N Engl J Med; 1996 May; 334(20):1333; author reply 1334-5. PubMed ID: 8609956 [No Abstract] [Full Text] [Related]
10. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]. Sudhop T; von Bergmann K MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862 [No Abstract] [Full Text] [Related]
11. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816 [TBL] [Abstract][Full Text] [Related]
12. [Primary and secondary prevention of coronary disease by statins]. Ferrières J Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337 [TBL] [Abstract][Full Text] [Related]
13. [Statin treatment in type 2 diabetes. Is it a must today?]. Faust M MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527 [No Abstract] [Full Text] [Related]
14. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS). Lim PO; Yee KM Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109 [No Abstract] [Full Text] [Related]
15. The effect of pravastatin on coronary events after myocardial infarction. Auerbach I; Behar S; Motro M N Engl J Med; 1997 Mar; 336(13):962. PubMed ID: 9072702 [No Abstract] [Full Text] [Related]
17. Long-term follow-up of the West of Scotland Coronary Prevention Study. DeFilippis AP; Bansal S; Blumenthal RS N Engl J Med; 2008 Jan; 358(2):194; author reply 194-5. PubMed ID: 18193527 [No Abstract] [Full Text] [Related]
18. [Effect of pharmacological interventions on progression of coronary atherosclerosis]. Navarro A Rev Esp Cardiol; 1996 May; 49(5):389-90. PubMed ID: 8744396 [No Abstract] [Full Text] [Related]
19. [Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world]. Poli A; Menotti A G Ital Cardiol; 1999 Oct; 29(10):1123-30. PubMed ID: 10546121 [No Abstract] [Full Text] [Related]
20. Long-term follow-up of the West of Scotland Coronary Prevention Study. Tsubokura M; Kami M N Engl J Med; 2008 Jan; 358(2):193-4; author reply 194-5. PubMed ID: 18193526 [No Abstract] [Full Text] [Related] [Next] [New Search]